Aperta NSE™ PTA
Peripheral artery disease
CommercialActive
Key Facts
About Nipro Medical
Nipro Medical Corporation, founded in 1984 and headquartered in Clearwater, Florida, is a commercial-stage medical device company operating in the renal care and vascular intervention markets. It is a key regional arm of the Japanese Nipro Group, leveraging global R&D to serve the North American market with products like the SURDIAL™ DX hemodialysis system and the Makoto™ intravascular imaging platform. The company is revenue-generating, supported by a broad portfolio of commercial products and a recent manufacturing expansion in Greenville, NC, indicating a commitment to growth and operational scale in the region.
View full company profileTherapeutic Areas
Other Peripheral artery disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Peripheral Artery Disease Program | Elixir Medical | Pre-clinical |
| JTV-263 | Akros Pharma | Phase1 |
| Luminor DCB | iVascularU | Post-Market |
| iVolution pro Stent | iVascularU | Post-Market |
| FGF-1 | Zhittya Genesis Medicine | Phase 2 |
| ChampioNIR | Medinol | Investigational |
| Peripheral Stent | Advanced Biomed | Approved |
| Ranger DCB | Boston Scientific | Pivotal Trial |